University of Groningen
Optimizing levofloxacin dose in the treatment of multidrug-resistant tuberculosis Ghimire, Samiksha
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Ghimire, S. (2019). Optimizing levofloxacin dose in the treatment of multidrug-resistant tuberculosis: An integrated PK/PD approach. University of Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
PROPOSITIONS
1. Dosing of fluoroquinolones has been too low – and this has created more problems than it has resolved. (This thesis)
2. Pre-extensively drug resistant TB is partly man made due to inadequate dosing of levofloxacin. (This thesis)
3. The under-dosing of first-line TB drugs has led to increased use of second line drugs. 4. Pharmacokinetic/pharmacodynamic based approach considering AUC/MIC ratio for
levofloxacin could help clinicians select the right dose for the treatment of MDR-TB patients. (This thesis)
5. Multi-drug regimens require multi-analyte assays for optimal work flow. (This thesis) 6. It is high time that national TB programs integrate Therapeutic Drug Monitoring (TDM)
as a core component alongside TB diagnostics and supply of first- and second- line drugs. (This thesis)
7. Saliva is an excellent screening matrix for levofloxacin exposure. (This thesis) 8. The future of TDM lies on micro-sampling techniques using limited time-points.
9. When you come out of the storm, you won't be the same person who walked in. (Haruki Murakami)
10. Nowhere is home. Everywhere is home. (Ben A. Wise)
